n BACKGROUND AND OBJECTIVE: To compare the success and complication rates of patients with glaucoma who had an Ex-PRESS mini glaucoma shunt device implantation (Optonol, Ltd., Neve Ilan, Israel) to those who had conventional trabeculectomy.
n PATIENTS AND METHODS: The records of 76 eyes of 69 consecutive subjects who had Ex-PRESS implants and 77 eyes of 65 consecutive controls who had trabeculectomy procedures were reviewed. All surgeries were performed by one of the authors (LWH). Success was defined as an intraocular pressure (IOP) between 5 and 21 mm Hg in patients who did not require further glaucoma surgery in the eye of note.
n RESULTS: The difference in the percentage of cases of postoperative hypotony between the standard trabeculectomy group (16%) and the Ex-PRESS group (4%) was statistically significant (P = .023).
n CONCLUSION: The Ex-PRESS device is at least as effective as the standard trabeculectomy in lowering the IOP of patients with glaucoma, with a significantly lower risk of postoperative hypotony. The data further suggest that the Ex-PRESS device results in an overall greater percentage reduction in IOP than with trabeculectomy, although this did not reach statistical significance. However, conventional trabeculectomy is still associated with a significant rate of postoperative complications including early hypotony, blebitis, and endophthalmitis, particularly when antimetabolites are used. 4 The Ex-PRESS mini glaucoma shunt (Optonol, Ltd., Neve Ilan, Israel) is a small, stainless steel, nonvalved shunt designed to lower IOP. An animal study using rabbits demonstrated that the implant was associated with little to no inflammatory reaction once implanted. 5 The Ex-PRESS apparatus was originally tested and placed directly under the conjunctiva and drained aqueous from the anterior chamber to the subconjunctival space. This resulted in a conjunctival filtering bleb, similar to a conventional trabeculectomy. 6 The aforementioned method was associated with conjunctival erosion above the Ex-PRESS device and scar formation resulting in bleb failure. 7, 8 The Ex-PRESS device is now routinely implanted under a partialthickness scleral flap, first described by Dahan and Carmichael, 9 and has been associated with few to no untoward effects. The implantation technique is relatively simple to perform for experienced glaucoma surgeons. Implantation of the Ex-PRESS device is considered less traumatic to the eye than traditional trabeculectomy. 10 Anecdotally, a growing number of glaucoma surgeons are using the Ex-PRESS modified trabeculectomy instead of the conventional trabeculectomy. There is little data comparing the two procedures. 10 In the current study, we compare the success and complication rates associated with standard trabeculectomy and trabeculectomy augmented by the Ex-PRESS device when performed by a single surgeon.
PATIENTS AND METHODS
This study was a retrospective comparison of patients who underwent either trabeculectomy or Ex-PRESS device placement by one of the authors (LWH) at a single center. The study protocol was approved by the Institutional Review Board and informed consent was obtained prior to each surgery. The records were reviewed of 77 eyes of 65 consecutive controls who had standard trab- 
Eligibility Criteria
Eligibility criteria for the study included uncontrolled glaucoma despite receiving maximal medical therapy or failed previous glaucoma surgeries (Table 1) . When a visually significant cataract was present, glaucoma procedures were combined with phacoemulsification and intraocular lens replacement. Patients met the same criteria in both groups.
Surgical Technique
Standard trabeculectomy procedures were performed by first creating a limbus-or fornix-based conjunctival flap. A partial-thickness scleral flap was then created using a Beaver Safety Sideport knife (BeaverVisitec, Waltham, MA) and forceps. MMC 0.4 mg/mL sponges were placed directly on top of and around the scleral flap for a duration of 30 seconds to 5 minutes. Balanced salt solution was used to copiously irrigate the tissues. A Kelly punch was used to fashion a sclerostomy, followed by the creation of an iridectomy with Vannas scissors. The scleral flap was re-approximated with interrupted 10-0 nylon sutures. Balanced salt solution was instilled into the anterior chamber and the conjunctival flap was closed with 8-0 Vicryl sutures (Ethicon, Inc., Somerville, NJ).
Ex-PRESS implantations were performed using either a limbus-or fornix-based conjunctival flap. A Sideport knife and forceps were then used to create a trapezoidal partial-thickness scleral flap that was folded back onto the sclera. MMC 0.4 mg/mL sponges were placed under the flap for 30 seconds to 5 minutes, after which time the eye was copiously irrigated with balanced salt solution. A 23-gauge needle was then used to create a sclerostomy underneath the scleral flap that projected into the anterior chamber. This created the opening through which the Ex-PRESS shunt could be inserted. The scleral flap was sutured over the Ex-PRESS shunt using two 10-0 nylon sutures. The conjunctival wound was reattached using two 10-0 Vicryl sutures at each end. Balanced salt solution was instilled to reform the anterior chamber and to elevate the bleb.
In eyes that underwent concurrent phacoemulsification and IOL implantation, the Ex-PRESS shunt was placed through the entry site into the anterior chamber (under the scleral flap). The fornix-based flap was sutured using 10-0 Vicryl sutures.
In both procedures, subconjunctival triamcinolone and topical steroid and antibiotic medications were given after the surgical wound was closed. Medications were tapered accordingly, but were prolonged in the case of prolonged inflammation.
Patient Information
The patient information recorded included gender, age, race, type of glaucoma, IOP (measured by Goldmann applanation), visual acuity, previous ocular surgeries, other ocular diseases, and preoperative and postoperative glaucoma medications. Patients were seen preoperatively and scheduled for follow-up visits on postoperative day 1, week 1, and months 1, 3, 6, 12, and 15. Patient information from the most recent clinical visit was also used in the data analysis.
Outcome Criteria
The primary outcomes assessed in the current study were IOP at the most recent clinic visit and the rate of postoperative complications. The maximum follow-up period was 16 months for the Ex-PRESS group and 18 months for the trabeculectomy group. Success was defined as having an IOP from 5 to 21 mm Hg. We chose 5 mm Hg as the cutoff point for hypotony based on the Glaucoma Research Foundation's definition of when a hypotonus eye may become problematic. 11 Failure was defined by having any of the following: IOP greater than 21 mm Hg on the most recent clinic visit, IOP less than 5 mm Hg, or the need to have further glaucoma surgery on the eye of note within the follow-up period of 15 months. Secondary outcomes that were assessed included the number of postoperative medications and the need for nonoperative procedures such as laser suture lysis, 5-fluorouracil (5-FU) injection, bleb needling, and ophthalmic viscoelastic device injection for anterior chamber reformation. Complete success was defined as meeting the original success criteria and not requiring any glaucoma medications for IOP control postoperatively. Qualified success was defined as meeting the original success criteria, but requiring one or more glaucoma medications in the postoperative period to maintain IOP control. 
Statistical Analysis
Descriptive statistics for all variables were computed. The significance of the difference between the Ex-PRESS group and the trabeculectomy group was assessed using the Fisher exact test for categorical variables and using the Wilcoxon rank test for continuous variables. The significance of the differences between other subgroups of variables was assessed similarly. P values of less than .05 were considered statistically significant.
RESULTS
A total of 134 patients were enrolled: 77 eyes (65 patients) underwent standard trabeculectomy and 76 eyes (69 patients) received Ex-PRESS implants. Patient's ages ranged from 16 to 95 years (mean: 66.8 ± 13.9 years in the trabeculectomy group and 66.9 ± 15.2 years in the Ex-PRESS group). Of the 124 patients, 20 trabeculectomy patients and 19 Ex-PRESS patients had glaucoma surgeries combined with phacoemulsification. The follow-up time (mean ± standard deviation) was 9.1 ± 3.5 months for the Ex-PRESS group and 9.2 ± 4.9 months for the trabeculectomy group. No significant differences existed between the two groups regarding age, gender, race, type of glaucoma, history of previous glaucoma surgery, or number of glaucoma medications (Table 1) . Figure 1 and Table 2 show the mean preoperative and postoperative IOP for the Ex-PRESS and trabeculectomy groups at postoperative day 1, week 1, month 1, and the most recent visit. The Ex-PRESS and standard trabeculectomy groups had statistically similar mean IOPs preoperatively (P = .062). The mean IOP was also statistically similar in the two groups at postoperative week 1, month 1, and the most recent visit (P = .112, .832, and .981, respectively). However, the Ex-PRESS group had significantly lower mean IOP at postoperative day 1 than the control group (11.3 and 16.1 mm Hg, respectively; P = .003). Figure 2 shows that the Ex-PRESS group had a statistically greater percent reduction in IOP from baseline on postoperative day 1 and week 1. After week 1, there was no difference in the percent of IOP reduction for the two groups, with an average 42% reduction in both groups.
The Ex-PRESS group had an overall greater surgical success rate than the standard trabeculectomy group (62 of 76 [82%] and 55 of 77 [71%], respectively), although this did not reach statistical significance (P = .182). Of the Ex-PRESS group cases that met success criteria, 85% were complete successes and the remaining 15% were qualified successes. Of the standard trabeculectomy group cases that met success criteria, 75% were complete successes and the remaining 25% were qualified successes. The difference between complete success rates in the two groups was not statistically significant (P = .0861). The Ex-PRESS group had a small but significantly greater reduction in preoperative to postoperative medications compared with the trabeculectomy group (87% vs 81%, P = .023; Table 3) .
Patients who had visually significant cataracts had their procedures combined with phacoemulsification when indicated. In both the Ex-PRESS and standard trabeculectomy arms of the study, subgroup analysis was done on subjects who had their procedures with and without phacoemulsification ( Table 4) . There were 19 patients in the Ex-PRESS group and 20 patients in the standard trabeculectomy group who underwent combined procedures. The mean preoperative IOP was similar in both groups. The combined standard trabeculectomy and phacoemulsification group had significantly higher IOPs on postoperative day 1, week 1, and month 1 than the standard trabeculectomy patients who did not undergo phacoemulsification. At the most recent visit, there were no differences between the two groups. There were no differences in IOP outcomes at any time points for either Ex-PRESS group (with or without concurrent phacoemulsification).
In the Ex-PRESS group, there were a total of 14 surgical failures: 7 because they had an IOP outside of the success criteria recorded at their most recent visit and 8 because they required further glaucoma surgery in the eye of note (one patient was in both categories). In the standard trabeculectomy group, there were 22 failures: 14 because of an IOP outside of the success criteria recorded at the most recent visit and 13 because they required further glaucoma surgery in the eye of note (five patients were in both categories).
There were no significant differences in the number of times laser suture lysis, a procedure to control IOP postoperatively, was done in the two groups. In the Ex-PRESS group, 34 laser suture lysis procedures were required, whereas in the standard trabeculectomy group, 41 laser suture lysis procedures were required (P = .329). There was no significant difference in the number of times 5-FU was administered to prevent bleb fibrosis in the postoperative period (two times in each group). Bleb needling, a procedure used to salvage a failing bleb, was performed one time in each group.
Postoperative complications for the two groups are summarized in Table 5 . A much greater percentage of cases of hypotony occurred in the standard trabeculectomy group (16%) compared with the Ex-PRESS group (4%), which was statistically significant (P = .023). There were no other statistically significant differences between the two groups for other postoperative complications.
DISCUSSION
The Ex-PRESS glaucoma mini shunt is a device that has been shown in previous studies to have good biocompatibility and aqueous flow control after implantation. 5, 9 Unlike standard trabeculectomy, the Ex-PRESS device is implanted without the creation of an iridectomy. We retrospectively compared the outcomes in a group of patients who had undergone standard trabeculectomy to those who had been implanted with the Ex-PRESS device. Our results indicated the Ex-PRESS device had a success rate comparable to standard trabeculectomy, when success is defined as having an IOP between 5 and 21 mm Hg without requiring further glaucoma surgery for at least 3 months postoperatively. Our results confirm those of Maris et al., 10 who found that the Ex-PRESS implant was similar in efficacy to the standard trabeculectomy. However, our results differ from those of Maris et al. in the reduction in glaucoma medications postoperatively. In our study, subjects in the Ex-PRESS group had an 87% reduction in glaucoma medication use compared with 81% for those in the standard trabeculectomy group (P = .023).
It is possible that the mean number of medications at baseline (3 in the Ex-PRESS group and 2.6 in the standard trabeculectomy group) could have a confounding influence on the percentage reductions we noted.
As in previous studies of Ex-PRESS devices implanted under a scleral flap, there were no cases of erosion of the device through the conjunctiva. 9, 10 This lends further support to the now widely accepted view that implantation of this device under the sclera is associated with a lower complication rate than one placed under the conjunctiva.
The standard trabeculectomy group showed differences in IOP at various postoperative time points between patients who had their procedures with and without phacoemulsification. This was most apparent at postoperative day 1 when the mean IOP was 26 and 12.9 mm Hg in those with and without phacoemulsification, respectively. There were no differences in IOP outcomes at any time point in the Ex-PRESS group, whether the procedure was done with or without phacoemulsification. This may be attributed to the less traumatic surgery with the Ex-PRESS shunt, because implantation does not require a peripheral iridectomy. Although not reported, our results found quieter eyes in the postoperative period in the Ex-PRESS group compared with the standard trabeculectomy group. Our results concur with previous published work about postoperative IOP after Ex-PRESS device implantation. 9, 10 Complications between the trabeculectomy and Ex-PRESS groups were not statistically significantly different except in the number of patients who developed early postoperative hypotony (16% in the standard trabeculectomy group and 4% in the Ex-PRESS group). Postoperative hypotony is a well-known complication of glaucoma filtration procedures; transient hypotony is also a well-known complication of trabeculectomy with intraoperative MMC use. There are several causes of postoperative hypotony after standard trabeculectomy, which are outside the parameters of this study to discuss. However, early post-trabeculectomy hypotony (within the first month) has been associated with a shorter survival time for the bleb. 12 Other studies have reported the incidence of postoperative hypotony after implantation with the Ex-PRESS device to range from 6% to 8.3%, 13 which is still well below rates reported for trabeculectomy. Our study showed a much lower incidence of postop- erative hypotony (4%). It has been suggested that the Ex-PRESS device offers additional protection when implanted under a scleral flap by increasing resistance to the aqueous flow and potentially reducing late conjunctival erosion.
14 Limitations of the current study include its nonrandomized and retrospective design, and in many cases a relatively short follow-up time.
This study demonstrates that the Ex-PRESS device is at least as effective in the management of glaucoma as standard trabeculectomy. Using the Ex-PRESS shunt is also associated with a lower rate of postoperative hypotony, as this and other studies have shown. 10 Our results support the use of Ex-PRESS device implantation as a viable alternative to the standard trabeculectomy.
